- Home
- CNMD vs DAWN Comparison
CNMD vs DAWN Comparison
Compare CNMD & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNMD | DAWN |
|---|---|---|
| Founded | 1970 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 1987 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CNMD | DAWN |
|---|---|---|
| Price | $38.81 | $11.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $53.67 | $27.56 |
| AVG Volume (30 Days) | 578.8K | ★ 2.8M |
| Earning Date | 01-28-2026 | 02-24-2026 |
| Dividend Yield | ★ 1.52% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.05 | N/A |
| Revenue | ★ $1,347,470,000.00 | $133,672,000.00 |
| Revenue This Year | $6.81 | $17.32 |
| Revenue Next Year | $0.93 | $53.42 |
| P/E Ratio | $19.31 | ★ N/A |
| Revenue Growth | 4.61 | ★ 31.11 |
| 52 Week Low | $38.32 | $5.64 |
| 52 Week High | $74.70 | $13.53 |
Technical Indicators
Market Signals| Indicator | CNMD | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 37.69 | 60.74 |
| Support Level | $40.69 | $11.60 |
| Resistance Level | $42.67 | $12.50 |
| Average True Range (ATR) | 1.72 | 0.97 |
| MACD | -0.30 | 0.14 |
| Stochastic Oscillator | 4.73 | 67.84 |
Price Performance
Historical ComparisonAbout CNMD CONMED Corporation
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East & Africa, Asia Pacific and North America. Majority is revenue is from USA.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.